detorsertib (GT0486) / Kintor Pharma - LARVOL DELTA

GT0486, a novel mTORC1/2 dual inhibitor, exhibits synergistic antitumor efficacy in combination with BTK inhibitors (AACR 2024) - "Compared with other mTOR inhibitors (GDC-0349, AZD-2014, Rapamycin, GDC-0941, and CC-223), GT0486 exhibits the stronger inhibitory activity on human tumor cells, such as U87(glioma), PC-3(prostate cancer), MDA-MB-468(breast cancer) and Huh-7(liver cancer)...High synergistic effects were observed with GT0486 in combination with BTK inhibitors, including Acalabrutinib, Ibrutinib, Zanubrutinib and Orelabrutinib in the BTKi sensitive TMD8 cells...These results demonstrate that GT0486 is a promising dual mTOR1/2 inhibitor, which is currently undergoing clinical phase I study in China for the treatment of solid tumors. Strong synergistic effects observed with GT0486 in combination with BTKi in this study might open a way for a novel treatment strategy in clinical trials."

Clinical • Combination therapy • Brain Cancer • Breast Cancer • CNS Tumor • Gastrointestinal Cancer • Genito-urinary Cancer • Glioma • Hematological Malignancies • Liver Cancer • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Prostate Cancer • Solid Tumor • EIF4EBP1

AACR 2024 Foreight | Three Oncology Studies From Kintor Pharma Selected (Kintor Pharma Press Release) - "In AACR 2024, one study of drug candidate GT0486 and two pre-clinical studies (including an anti-PD-1/ALK-1 bispecific antibody Nivo813 and a molecular glue GT19870) from Kintor Pharma are selected. It demonstrates high research and development value of drug and pre-clinical studies, also signifies that the company’s innovative capabilities and potential for drug development have been internationally recognized."

Preclinical • Solid Tumor